Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
Charles River Laboratories International, Inc. provides products and services used in drug discovery, early-stage development, safety assessment, and the manufacture of new therapies. Company news commonly covers results from its Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions activities, along with updates on research models, nonclinical toxicology, microbial and biologics testing, and client demand trends.
Recurring developments also include digital pathology initiatives, AI-enabled workflow tools, rat in vitro fertility services, virtual control groups, and the Alternative Methods Advancement Project™, which relate to efficiency and reduced animal use where scientifically appropriate. Financial releases, investor presentations, governance updates, and portfolio changes are also recurring disclosure themes for CRL.
Charles River Laboratories (CRL) and MEDIPOST signed a strategic, non-exclusive MOU to collaborate on GMP-compliant testing and joint commercial and marketing efforts for cell therapies.
The agreement supports MEDIPOST’s global cell therapy pipeline, initially in APAC and North America, leveraging Charles River’s biologics quality control, viral and release testing expertise.
Charles River (NYSE: CRL) announced an AI-enabled, end-to-end digital pathology workflow designed to cut at least one week from standard pathology timelines while maintaining GLP standards and regulatory readiness.
The platform integrates LIMS, AI-powered slide QC, GLP-validated digital primary reviews, and decision-support tools that may boost pathologist efficiency and support 3R-aligned animal reduction through Virtual Control Groups.
Charles River Laboratories (NYSE: CRL) reported Q1 2026 revenue $995.8M, GAAP loss per share $(0.30) and non-GAAP EPS $2.06. The company completed the CDMO and Cell Solutions divestiture on May 6, 2026, repurchased $200M of stock in Q1, and reaffirmed 2026 organic revenue and non-GAAP EPS guidance.
Q1 results reflected a 1.2% reported revenue increase, a GAAP net loss driven by an $118.0M loss on assets held for sale, and lower non-GAAP operating margin vs. prior year.
Charles River (NYSE: CRL) launched commercial rat In Vitro Fertility (IVF) services on April 30, 2026, positioning itself as the first commercial provider for rat-model IVF. The service bundle includes embryo transfer, cryopreservation, rederivation, dedicated project management, optional health monitoring, and genetic validation.
Charles River says the offering aims to shorten breeding timelines, reduce animal use, recover valuable lines, expand cohorts, and maintain VAF/Elite (SOPF) health standards; streamlined quotes and timelines are available starting this quarter.
Charles River (NYSE: CRL) reported a peer-reviewed retrospective analysis showing Virtual Control Groups (VCGs) matched concurrent controls for key outcomes in 20 toxicology studies. The review found 100% concordance in NOAEL and noted up to a 25% reduction in control-animal use where appropriate. The company highlighted ongoing refinement, collaboration via the VICT3R consortium, and an EMA draft qualification step toward broader regulatory acceptance of VCGs.
Charles River Laboratories (NYSE: CRL) will release first-quarter 2026 financial results on Thursday, May 7, 2026, before the market opens. A conference call to discuss results is scheduled the same day at 8:30 a.m. ET. Investors can listen via live webcast at the company's Investor Relations site and access a replay there.
Charles River (NYSE: CRL) announced a collaboration with the American Heart Association to support cardiovascular disease awareness, prevention, and community health initiatives, including backing the Heart of Boston campaign.
The partnership aligns with Charles River's corporate purpose and citizenship strategy to advance public health amid persistent cardiovascular risk factors noted in 2026 statistics.
NYSE (NYSE: CRL) issues a pre-market update for April 6, 2026, delivering floor-based market insights ahead of trading.
Key items: Kristen Scholer presents the pre-market update; NYSE partners with AI conference HumanX in San Francisco with Ashley Mastronardi on site; James Foster, Chairman, President and CEO of Charles River Laboratories (CRL), will appear on NYSE Live; Mikaela Shiffrin rang the Closing Bell. For market coverage and opening bell details, download the NYSE TV App at TV.NYSE.com.
Charles River Laboratories (NYSE: CRL) will present at two investor conferences in March 2026: TD Cowen on March 3, 2026 at 9:50 a.m. ET and Barclays on March 10, 2026 at 10:00 a.m. ET. Management will discuss strategic focus, business developments, and recent trends.
A live webcast link will be posted on the company's Investor Relations website at ir.criver.com, and replays will remain available for at least two weeks after each presentation.
Charles River Laboratories (NYSE: CRL) signed definitive agreements to divest its CDMO and Cell Solutions businesses to GI Partners and certain European Discovery Services assets to IQVIA for approximately $145 million in cash plus up to $10 million in additional payments. The deals cover sites in the US, UK, and Europe and generated combined 2025 revenue cited at $143 million (CDMO and Cell Solutions) and $144 million (divested discovery capabilities). Both transactions are expected to close in Q2 2026, subject to customary conditions. The company updated 2026 guidance, estimating slightly more than $200 million lower reported revenue, a >50-basis-point reduction to organic growth, at least 100 basis points of incremental non-GAAP operating margin improvement, and roughly $0.10 accretion to non-GAAP EPS for the partial year.